New Research Reveals Probiotic Impact on NEC in Preterm Infants
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: Newsfilter
- Research Background: Pediatrix Medical Group's new study investigates the relationship between probiotic use and necrotizing enterocolitis (NEC) in preterm infants, utilizing data from over 10,000 extremely preterm infants in the Pediatrix Clinical Data Warehouse, highlighting the database's significance in neonatal outcome research.
- Rising NEC Rates: The study found that rates of NEC significantly increased in hospitals following the FDA's 2023 warnings and market withdrawal of probiotics, indicating that the abrupt cessation of probiotics may have had unintended negative consequences for this vulnerable population.
- Observational Study Limitations: While the findings support the notion that probiotics may help protect preterm infants from NEC, the study did not identify which probiotic strains, doses, or products might be most effective or safest, underscoring the need for future prospective clinical trials.
- Collaboration and Advocacy: The NEC Society collaborated with Pediatrix on this research, emphasizing the importance of cooperation among clinicians, scientists, and families to bridge scientific gaps and improve care for preterm infants, aiming to create a better survival environment for all babies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MD
Wall Street analysts forecast MD stock price to fall
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 24.160
Low
23.00
Averages
23.50
High
24.00
Current: 24.160
Low
23.00
Averages
23.50
High
24.00
About MD
Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
New Research Reveals Probiotic Impact on NEC in Preterm Infants
- Research Background: Pediatrix Medical Group's new study investigates the relationship between probiotic use and necrotizing enterocolitis (NEC) in preterm infants, utilizing data from over 10,000 extremely preterm infants in the Pediatrix Clinical Data Warehouse, highlighting the database's significance in neonatal outcome research.
- Rising NEC Rates: The study found that rates of NEC significantly increased in hospitals following the FDA's 2023 warnings and market withdrawal of probiotics, indicating that the abrupt cessation of probiotics may have had unintended negative consequences for this vulnerable population.
- Observational Study Limitations: While the findings support the notion that probiotics may help protect preterm infants from NEC, the study did not identify which probiotic strains, doses, or products might be most effective or safest, underscoring the need for future prospective clinical trials.
- Collaboration and Advocacy: The NEC Society collaborated with Pediatrix on this research, emphasizing the importance of cooperation among clinicians, scientists, and families to bridge scientific gaps and improve care for preterm infants, aiming to create a better survival environment for all babies.
See More
Pediatrix Medical Group Q1 2026 Earnings Call Insights
- Strong Financial Performance: Pediatrix Medical Group reported an adjusted EBITDA of $58 million for Q1 2026, reflecting a decline from $66 million in the previous quarter, yet demonstrating robust revenue growth that indicates stability in the market.
- Revenue Growth Drivers: The company noted a same-unit growth of nearly 3% and net non-same unit activity contributing about $6 million, despite some revenue declines due to portfolio restructuring, showcasing the potential from acquisitions and organic growth.
- Cash Flow and Capital Management: In Q1, the company utilized $130 million in operating cash flow and deployed $21 million in capital to repurchase 1 million shares, indicating a proactive approach to capital management while maintaining over $200 million in cash reserves and $385 million in net debt.
- Future Outlook and Challenges: Management reaffirmed the adjusted EBITDA outlook for 2026 at $280 million to $300 million, acknowledging potential risks from declining patient volumes and revenues in hospital systems, yet expressing optimism about stability and emphasizing the need to remain cautious regarding subsidy impacts.
See More
Pediatrix Medical Group Reports Q1 Revenue of $476.196 Million, Exceeding IBES Estimate of $465.8 Million
- Pediatrix Medical Group Revenue: Pediatrix Medical Group reported a revenue of USD 476.196 million for Q1.
- Comparison with Estimates: This revenue figure exceeds the estimates from IBES, which were USD 465.8 million.
See More
Pediatrix Medical Group Reports Q1 Operating Expenses of $434.539 Million
- Financial Overview: PediaTric Medical Group reported operating expenses totaling USD 434.539 million for Q1.
- Budget Implications: The significant operating expenses may impact future financial planning and resource allocation for the organization.
See More
Pediatrix Medical Group Q1 Earnings Announcement Scheduled
- Earnings Release Date: Pediatrix Medical Group is set to announce its Q1 earnings on May 5 before market open, with a consensus EPS estimate of $0.38, reflecting a 15.2% year-over-year growth, indicating robust profitability trends.
- Revenue Expectations: The anticipated Q1 revenue is $465.82 million, representing a 1.6% year-over-year increase, which, while modest, still demonstrates ongoing demand and stability in the healthcare services sector.
- Historical Performance: Over the past two years, Pediatrix has beaten EPS estimates 88% of the time and revenue estimates 75% of the time, a strong performance record that may bolster investor confidence ahead of the earnings announcement.
- Future Outlook: The company anticipates adjusted EBITDA of $280 million to $300 million in 2026, focusing on practice alignment and telemedicine, indicating a proactive approach to adapting to evolving trends in the healthcare industry.
See More
Pediatrix Expands Maternal-Fetal Care in Tennessee
- Service Expansion: Pediatrix Medical Group enhances its service network in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine, ensuring high-quality maternal-fetal care for expectant mothers in the Greater Nashville area and strengthening its market position in this sector.
- Expert Team: The practice comprises four board-certified physicians and six advanced practice providers, offering comprehensive maternal-fetal medicine services, thereby enhancing Pediatrix's ability to meet the growing maternal care needs in Middle Tennessee.
- Strategic Partnership: This collaboration not only elevates Pediatrix's specialty services but also integrates the national reputation of Tennessee Maternal-Fetal Medicine, which is expected to positively impact the company's future revenue streams.
- Financial Impact: The transaction is a cash deal and is anticipated to be immediately accretive to Pediatrix's earnings, further solidifying its leadership position in the maternal-fetal medicine market.
See More
New Research Reveals Probiotic Impact on NEC in Preterm Infants
- Research Background: Pediatrix Medical Group's new study investigates the relationship between probiotic use and necrotizing enterocolitis (NEC) in preterm infants, utilizing data from over 10,000 extremely preterm infants in the Pediatrix Clinical Data Warehouse, highlighting the database's significance in neonatal outcome research.
- Rising NEC Rates: The study found that rates of NEC significantly increased in hospitals following the FDA's 2023 warnings and market withdrawal of probiotics, indicating that the abrupt cessation of probiotics may have had unintended negative consequences for this vulnerable population.
- Observational Study Limitations: While the findings support the notion that probiotics may help protect preterm infants from NEC, the study did not identify which probiotic strains, doses, or products might be most effective or safest, underscoring the need for future prospective clinical trials.
- Collaboration and Advocacy: The NEC Society collaborated with Pediatrix on this research, emphasizing the importance of cooperation among clinicians, scientists, and families to bridge scientific gaps and improve care for preterm infants, aiming to create a better survival environment for all babies.
See More
Pediatrix Medical Group Q1 2026 Earnings Call Insights
- Strong Financial Performance: Pediatrix Medical Group reported an adjusted EBITDA of $58 million for Q1 2026, reflecting a decline from $66 million in the previous quarter, yet demonstrating robust revenue growth that indicates stability in the market.
- Revenue Growth Drivers: The company noted a same-unit growth of nearly 3% and net non-same unit activity contributing about $6 million, despite some revenue declines due to portfolio restructuring, showcasing the potential from acquisitions and organic growth.
- Cash Flow and Capital Management: In Q1, the company utilized $130 million in operating cash flow and deployed $21 million in capital to repurchase 1 million shares, indicating a proactive approach to capital management while maintaining over $200 million in cash reserves and $385 million in net debt.
- Future Outlook and Challenges: Management reaffirmed the adjusted EBITDA outlook for 2026 at $280 million to $300 million, acknowledging potential risks from declining patient volumes and revenues in hospital systems, yet expressing optimism about stability and emphasizing the need to remain cautious regarding subsidy impacts.
See More
Pediatrix Medical Group Reports Q1 Revenue of $476.196 Million, Exceeding IBES Estimate of $465.8 Million
- Pediatrix Medical Group Revenue: Pediatrix Medical Group reported a revenue of USD 476.196 million for Q1.
- Comparison with Estimates: This revenue figure exceeds the estimates from IBES, which were USD 465.8 million.
See More
Pediatrix Medical Group Reports Q1 Operating Expenses of $434.539 Million
- Financial Overview: PediaTric Medical Group reported operating expenses totaling USD 434.539 million for Q1.
- Budget Implications: The significant operating expenses may impact future financial planning and resource allocation for the organization.
See More
Pediatrix Medical Group Q1 Earnings Announcement Scheduled
- Earnings Release Date: Pediatrix Medical Group is set to announce its Q1 earnings on May 5 before market open, with a consensus EPS estimate of $0.38, reflecting a 15.2% year-over-year growth, indicating robust profitability trends.
- Revenue Expectations: The anticipated Q1 revenue is $465.82 million, representing a 1.6% year-over-year increase, which, while modest, still demonstrates ongoing demand and stability in the healthcare services sector.
- Historical Performance: Over the past two years, Pediatrix has beaten EPS estimates 88% of the time and revenue estimates 75% of the time, a strong performance record that may bolster investor confidence ahead of the earnings announcement.
- Future Outlook: The company anticipates adjusted EBITDA of $280 million to $300 million in 2026, focusing on practice alignment and telemedicine, indicating a proactive approach to adapting to evolving trends in the healthcare industry.
See More
Pediatrix Expands Maternal-Fetal Care in Tennessee
- Service Expansion: Pediatrix Medical Group enhances its service network in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine, ensuring high-quality maternal-fetal care for expectant mothers in the Greater Nashville area and strengthening its market position in this sector.
- Expert Team: The practice comprises four board-certified physicians and six advanced practice providers, offering comprehensive maternal-fetal medicine services, thereby enhancing Pediatrix's ability to meet the growing maternal care needs in Middle Tennessee.
- Strategic Partnership: This collaboration not only elevates Pediatrix's specialty services but also integrates the national reputation of Tennessee Maternal-Fetal Medicine, which is expected to positively impact the company's future revenue streams.
- Financial Impact: The transaction is a cash deal and is anticipated to be immediately accretive to Pediatrix's earnings, further solidifying its leadership position in the maternal-fetal medicine market.
See More
